[New antibiotics - standstill or progress].
The development of resistance to antibiotics has been ignored for a long time. But nowadays, increasing resistance is an important topic. For a decade no new antibiotics had been developed and it is not possible to quickly close this gap of new resistance and no new drugs. This work presents six new antibiotics (ceftaroline, ceftobiprole, solithromycin, tedizolid, ceftolozane/tazobactam, ceftazidime/avibactam). In part, only expert opinions are given due to lack of study results.The two 5th generation cephalosporins ceftaroline and ceftobiprole have beside their equivalent efficacy to ceftriaxone (ceftaroline) and cefipim (ceftobiprole) high activity against MRSA. The fluoroketolide solithromycin should help against macrolide-resistant pathogens and has been shown to be noninferior to the fluorochinolones. The oxazolidinone tedizolid is effective against linezolid-resistant MRSA. The two cephalosporins ceftolozane/tazobactam and ceftazidime/avibactam are not only effective against gram-negative pathogens, but they have a very broad spectrum. Due to the efficacy against extended-spectrum β‑lactamases, they can relieve the selection pressure of the carbapenems. We benefit from all new antibiotics which can take the selection pressure from other often used antibiotics. The increasing number of resistant gram-negative pathogens worldwide is alarming. Thus, focusing on the development of new drugs is extremely important.
Klinik für Pneumologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 306125, Hannover, Deutschland. rademacher.jessica@mh-hannover.de.
J
J
Rademacher
Klinik für Pneumologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 306125, Hannover, Deutschland.
T
T
Welte
D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D053961:Azabicyclo Compounds / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D002442:Ceftazidime / Q000627:therapeutic use; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004338:Drug Combinations; D024901:Drug Resistance, Multiple, Bacterial; D004809:Ephedrine; D006801:Humans; D018942:Macrolides / Q000009:adverse effects / Q000627:therapeutic use; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D010755:Organophosphates / Q000009:adverse effects / Q000627:therapeutic use; D010080:Oxazoles / Q000009:adverse effects / Q000627:therapeutic use; D010397:Penicillanic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D010634:Phenobarbital; D013203:Staphylococcal Infections / Q000188:drug therapy; D000078142:Tazobactam; D013806:Theophylline; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use; D000097583:Ceftaroline
D000900:Anti-Bacterial Agents; D053961:Azabicyclo Compounds; D002442:Ceftazidime; D002511:Cephalosporins; D004338:Drug Combinations; D004809:Ephedrine; D018942:Macrolides; D010755:Organophosphates; D010080:Oxazoles; D010397:Penicillanic Acid; D010634:Phenobarbital; D000078142:Tazobactam; D013806:Theophylline; D014230:Triazoles; D000097583:Ceftaroline; C000595613:avibactam, ceftazidime drug combination; C000594038:ceftolozane, tazobactam drug combination; C443755:ceftobiprole; C009390:ephedrine, phenobarbital, theophylline drug combination; C547755:solithromycin; C515040:tedizolid phosphate
Beta-lactam resistance; Cephalosporins; Drug resistance, bacterial; Infection; MRSA